[Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples].

Abstract

Plasminogen activator inhibitor-1 (PAI-1) may contribute to renal fibrosis because of its involvement in matrix (ECM) accumulation through inhibition of plasmin-dependent ECM degradation. The aim of this study is to determine urinary PAI-1 concentrations and its intrarenal localization in patients with various renal diseases and to identify inducers for PAI… (More)

Topics

Cite this paper

@article{Torii2004DiabeticNA, title={[Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples].}, author={Kunio Torii and Hideki Kimura and Xuan Li and Toshiharu Okada and Toshio Imura and Koji Oida and Isamu Miyamori and Fumio Furusaki and Tomoko Ono and Haruyoshi Yoshida}, journal={Rinsho byori. The Japanese journal of clinical pathology}, year={2004}, volume={52 6}, pages={506-12} }